Position in GNLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$79,269
-$280,884 QoQ
Shares Held
32,756
-60.3% QoQ
Ownership
0.073%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BARCLAYS PLC holds $1,494,072,071 across 362 Biotechnology names. GNLX ranks #254 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
663,263 | $296,173,457 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
313,093 | $241,908,173 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
220,623 | $72,997,531 | |
| 4 | MRNA |
Moderna, Inc.
|
932,269 | $47,359,264 | |
| 5 | INSM |
INSMED Inc
|
275,731 | $45,087,531 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
1,415,848 | $39,218,988 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
383,179 | $37,264,156 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
669,601 | $35,301,364 |
All Filings in GNLX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $79,269 | 32,756 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $360,153 | 82,604 | Shares | Sole | 2026-02-13 | |
| 2024-06-30 | $29,519 | 15,138 | Shares | Sole | 2026-03-23 | |
| 2024-03-31 | $86,342 | 13,428 | Shares | Sole | 2026-03-24 | |
| 2023-12-31 | $356,764 | 25,465 | Shares | Sole | 2026-03-24 | |
| 2023-09-30 | $82,874 | 3,384 | Shares | Sole | 2026-03-26 | |
| 2023-06-30 | $17,963 | 549 | Shares | Sole | 2026-03-27 | |
| 2023-03-31 | $920,357 | 33,178 | Shares | Sole | 2026-03-30 | |
| No filing history on record for this holder in this stock. | ||||||